ImmunityBio’s (IBRX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a report issued on Wednesday morning,Benzinga reports. D. Boral Capital currently has a $24.00 price objective on the stock.

IBRX has been the topic of a number of other reports. Weiss Ratings reissued a “sell (e+)” rating on shares of ImmunityBio in a research note on Tuesday, October 14th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of ImmunityBio in a research report on Wednesday, September 10th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, ImmunityBio currently has an average rating of “Moderate Buy” and a consensus price target of $10.75.

ImmunityBio Price Performance

ImmunityBio stock traded up $0.01 during mid-day trading on Wednesday, hitting $2.13. The company’s stock had a trading volume of 10,634,042 shares, compared to its average volume of 9,410,209. ImmunityBio has a 12 month low of $1.83 and a 12 month high of $5.88. The business has a 50 day moving average price of $2.48 and a 200-day moving average price of $2.58. The stock has a market cap of $2.10 billion, a price-to-earnings ratio of -5.20 and a beta of 0.29.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10). The company had revenue of $26.43 million during the quarter, compared to the consensus estimate of $21.95 million. On average, equities research analysts expect that ImmunityBio will post -0.92 earnings per share for the current fiscal year.

Institutional Trading of ImmunityBio

A number of large investors have recently made changes to their positions in IBRX. Slow Capital Inc. purchased a new stake in ImmunityBio in the 1st quarter valued at about $30,000. Financial Enhancement Group LLC purchased a new position in shares of ImmunityBio in the 2nd quarter worth approximately $28,000. Compound Planning Inc. bought a new position in shares of ImmunityBio during the 1st quarter worth approximately $30,000. Envision Financial Planning LLC purchased a new stake in ImmunityBio during the second quarter valued at approximately $28,000. Finally, Summit X LLC acquired a new stake in ImmunityBio in the second quarter valued at approximately $28,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.